2026: A watershed year for RNA therapeutics—From breakthrough vaccines to chronic indications and beyond

The year 2026 is shaping up to be a pivotal watershed year for therapeutic RNA. The rapid progression of mRNA technology—once accelerated by emergency pandemic responses—has officially entered a mature, highly diversified phase. Recent milestones from commercial leaders like Moderna demonstrate that mRNA is no longer a niche or temporary platform, but a permanent pillar of modern pharmacology. As highlighted in recent press releases, Moderna’s 2026 late-stage successes in both infectious diseases (such as their combination flu/COVID and next-generation influenza vaccines) and oncology (notably intismeran,1 the individualized neoantigen therapy evaluated alongside pembrolizumab) underscore a crucial transition: linear mRNA can deliver robust, reproducible expression with meaningful clinical endpoints across diverse disease settings.